Tirzepatide is a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management (Mounjaro) and chronic weight management (Zepbound) in adults with BMI 30 kg/m or 27 kg/m with at least one weight-related comorbidity
Can I switch clinics if I'm not satisfied with my current provider
Copay Assistance Programs For patients needing help with copays, various assistance programs, including the Eli Lilly Zepbound savings card, are available to reduce out-of-pocket expenses
Patients should contact their clinician or pharmacist about persistent or severe symptoms
53 Another recent, randomized, multicenter, open-label trial was conducted in the UK and studied whether targeting an albumin serum level 30 g/L would reduce the risk of infections, renal dysfunction and death in patients with decompensated cirrhosis
Tier 4: Environmental and nighttime strategies 13